$1.83
-0.26 (-12.44%)
Open$2.00
Previous Close$2.09
Day High$2.00
Day Low$1.54
52W High$71.50
52W Low$1.07
Volume—
Avg Volume6.2K
Market Cap3.34M
P/E Ratio—
EPS$-25.56
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+413.7% upside
Current
$1.83
$1.83
Target
$9.40
$9.40
$5.45
$9.40 avg
$11.97
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.71M | 2.16M | 1.98M |
| Net Income | -80,847,919 | -609,365 | -497,914 |
| Profit Margin | -2,980.4% | -28.2% | -25.1% |
| EBITDA | -80,482,977 | -937,252 | -843,277 |
| Free Cash Flow | — | -606,690 | -515,846 |
| Rev Growth | +100.0% | +2.0% | +14.6% |
| Debt/Equity | — | 0.62 | 0.60 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |